A recent study published on Thursday suggests that individuals taking popular weight loss medications may face a higher risk of serious digestive issues like stomach paralysis, pancreatitis, and bowel obstructions.
These medications, known as glucagon-like peptide 1 (GLP-1) agonists, are originally approved for diabetes treatment but have been increasingly used off-label for weight loss.
Conducted by researchers at the University of British Columbia and published in The Journal of the American Medical Association, the study analyzed a random sample of over 16 million insurance claims from a prescription drug database covering about 93 percent of all outpatient prescriptions in the U.S.
The focus was on examining gastrointestinal adverse events associated with the use of GLP-1 agonists for weight loss in clinical settings. The findings revealed an elevated risk of pancreatitis, bowel obstruction, and gastroparesis linked to the use of these medications.
The researchers emphasized that these complications are not to be taken lightly, particularly noting that bowel obstructions can escalate into medical emergencies.
Source – CGTN